Tomazoni Shaiane Silva, Casalechi Heliodora Leão, Ferreira Cheila de Sousa Bacelar, Serra Andrey Jorge, Dellê Humberto, Brito Rodrigo Barbosa de Oliveira, de Melo Brunno Lemes, Vanin Adriane Aver, Ribeiro Neide Firmo, Pereira Amanda Lima, Monteiro Kadma Karênina Damasceno Soares, Marcos Rodrigo Labat, de Carvalho Paulo de Tarso Camillo, Frigo Lucio, Leal-Junior Ernesto Cesar Pinto
Department of Global Public Health and Primary Care, Physiotherapy Research Group, University of Bergen, Bergen, Norway.
Laboratory of Phototherapy and Innovative Technologies in Health (LaPIT), Universidade Nove de Julho (UNINOVE), São Paulo, São Paulo, Brazil.
PLoS One. 2020 Aug 12;15(8):e0236689. doi: 10.1371/journal.pone.0236689. eCollection 2020.
To compare the effects of photobiomodulation therapy (PBMT) and pharmacological therapy (glucocorticoids and non-steroidal anti-inflammatory drugs) applied alone and in different combinations in mdx mice.
The animals were randomized and divided into seven experimental groups treated with placebo, PBMT, prednisone, non-steroidal anti-inflammatory drug (NSAIDs), PBMT plus prednisone and PBMT plus NSAID. Wild type animals were used as control. All treatments were performed during 14 consecutive weeks. Muscular morphology, protein expression of dystrophin and functional performance were assessed at the end of the last treatment.
Both treatments with prednisone and PBMT applied alone or combined, were effective in preserving muscular morphology. In addition, the treatments with PBMT (p = 0.0005), PBMT plus prednisone (p = 0.0048) and PBMT plus NSAID (p = 0.0021) increased dystrophin gene expression compared to placebo-control group. However, in the functional performance the PBMT presented better results compared to glucocorticoids (p<0.0001). In contrast, the use of NSAIDs did not appear to add benefits to skeletal muscle tissue in mdx mice.
We believe that the promising and optimistic results about the PBMT in skeletal muscle of mdx mice may in the future contribute to this therapy to be considered a safe alternative for patients with Duchenne Muscular Dystrophy (DMD) in a washout period (between treatment periods with glucocorticoids), allowing them to remain receiving effective and safe treatment in this period, avoiding at this way periods without administration of any treatment.
比较光生物调节疗法(PBMT)与药物疗法(糖皮质激素和非甾体抗炎药)单独及不同组合应用于mdx小鼠的效果。
将动物随机分为七个实验组,分别接受安慰剂、PBMT、泼尼松、非甾体抗炎药(NSAIDs)、PBMT加泼尼松以及PBMT加NSAIDs治疗。野生型动物作为对照。所有治疗均连续进行14周。在最后一次治疗结束时评估肌肉形态、抗肌萎缩蛋白的蛋白表达和功能表现。
单独或联合应用泼尼松和PBMT进行治疗,在保持肌肉形态方面均有效。此外,与安慰剂对照组相比,PBMT治疗组(p = 0.0005)、PBMT加泼尼松治疗组(p = 0.0048)和PBMT加NSAIDs治疗组(p = 0.0021)的抗肌萎缩蛋白基因表达增加。然而,在功能表现方面,PBMT与糖皮质激素相比呈现出更好的结果(p<0.0001)。相比之下,使用NSAIDs似乎并未给mdx小鼠的骨骼肌组织带来额外益处。
我们认为,关于PBMT在mdx小鼠骨骼肌中取得的有前景且乐观的结果,未来可能有助于该疗法在杜氏肌营养不良症(DMD)患者的洗脱期(糖皮质激素治疗周期之间)被视为一种安全的替代疗法,使他们在此期间能够继续接受有效且安全的治疗,从而避免出现无任何治疗的时期。